Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 7/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 8/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2675300 | 0.88 | CCR1 (0.39) | CCR1CHRM2CCR5DPP4REN | |
| SCHEMBL3825745 | 0.86 | CCR1 (0.60) | CCR1CHRM2CCR5DPP4REN | |
| SCHEMBL2676428 | 0.86 | CCR1 (0.60) | CCR1CHRM2CCR5DPP4REN | |
| SCHEMBL4389915 | 0.85 | CCR1 (0.48) | CCR1CHRM2CCR5DPP4REN | |
| SCHEMBL4067311 | 0.83 | CCR1 (0.48) | CCR1CHRM2CCR5REN | |
| SCHEMBL2676715 | 0.83 | CCR1 (0.47) | CCR1CHRM2CCR5RENRIPK1 | |
| SCHEMBL2675073 | 0.82 | CCR1 (0.57) | CCR1CHRM2CCR5 | |
| SCHEMBL2676322 | 0.81 | CCR1 (0.60) | CCR1CHRM2CCR5DPP4REN | |
| SCHEMBL4068828 | 0.78 | CCR1 (0.47) | CCR1CHRM2CCR5DPP4REN | |
| SCHEMBL4065303 | 0.78 | CCR1 (0.47) | CCR1CHRM2CCR5DPP4REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8257739-B2 | low-solubility drug (especially CCR-1 inhibitors) and a concentration-enhancing polymer; drug-rich regions are interspersed throughout drug-poor, polymer-rich regions; storage stability | BEND RESEARCH, INC. (US) | 2012-09-04 | — | — | US | claimed |
| EP-1051405-B1 | NOVEL DIHYDROXYHEXANOIC ACID DERIVATIVES | PFIZER PROD INC (US) | 2006-08-23 | — | — | EP | claimed |
| US-20040156905-A1 | Pharmaceutical compositions of semi-ordered drugs and polymers | PFIZER INC. | 2004-08-12 | — | — | US | claimed |
| WO-2004039375-A1 | METHODS OF USING CCR1 ANTAGONISTS AS IMMUNOMODULATORY AGENTS | PFIZER PRODUCTS INC. (US) | 2004-05-13 | — | — | WO | claimed |
| US-20040087571-A1 | Methods of using CCR1 antagonists as immunomodulatory agents | PFIZER INC | 2004-05-06 | — | — | US | claimed |
| US-6673801-B1 | TREATING MULTIPLE SCLEROSIS OR RHEUMATOID ARTHRITIS | PFIZER INC. | 2004-01-06 | — | — | US | claimed |
| US-20030018033-A1 | Novel dihydroxyhexanoic acid derivatives | KATH JOHN CHARLES (US) | 2003-01-23 | — | — | US | claimed |
| EP-1051405-A2 | NOVEL DIHYDROXYHEXANOIC ACID DERIVATIVES | Pfizer Products Inc. (US) | 2000-11-15 | — | — | EP | claimed |
| WO-1999040061-A2 | NOVEL DIHYDROXYHEXANOIC ACID DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1999-08-12 | — | — | WO | claimed |
| US-20160374945-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUG AND NEUTRAL POLYMERS | BEND RESEARCH, INC. (US) | 2016-12-29 | — | — | US | disclosed |
| US-9468604-B2 | Pharmaceutical compositions of dispersions of drug and neutral polymers | BEND RESEARCH, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20140210117-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUG AND NEUTRAL POLYMERS | BEND RESEARCH, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8703196-B2 | Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers | BEND RESEARCH, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703199-B2 | Pharmaceutical compositions of adsorbates of amorphous drug | BEND RESEARCH, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| EP-1269994-A2 | Pharmaceutical compositions comprising drug and concentration-enhancing polymers | Pfizer Products Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| US-6403587-B1 | AUTOIMMUNE DISEASES, ACUTE AND CHRONIC INFLAMMATORY CONDITIONS, ALLERGIC CONDITIONS, INFECTION ASSOCIATED WITH INFLAMMATION, VIRAL, TRANSPLANTATION TISSUE REJECTION, ATHEROSCLEROSIS, RESTENOSIS, HIV INFECTIVITY, AND | PFIZER INC. | 2002-06-11 | — | — | US | disclosed |
| EP-1051405-A2 | NOVEL DIHYDROXYHEXANOIC ACID DERIVATIVES | Pfizer Products Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| EP-0966443-A1 | HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR | PFIZER INC. (US) | 1999-12-29 | — | — | EP | disclosed |
| WO-1999040061-A2 | NOVEL DIHYDROXYHEXANOIC ACID DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1999-08-12 | — | — | WO | disclosed |
| WO-1998038167-A1 | HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR | PFIZER INC. (US) | 1998-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018033-A1 | Novel dihydroxyhexanoic acid derivatives | HCAR1, HCAR2, SLC27A1 | CCR1 180/4885CHRM2 3772/4885CCR5 307/4885 |
| US-20040087571-A1 | Methods of using CCR1 antagonists as immunomodulatory agents | CCR1, CCR3, CCRL2 | CCR1 1/4885CHRM2 492/4885CCR5 10/4885 |
| US-20040156905-A1 | Pharmaceutical compositions of semi-ordered drugs and polymers | ABCB1, ABCG2, PDE7A | CCR1 1295/4885CHRM2 2431/4885CCR5 2594/4885 |
| US-20160374945-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUG AND NEUTRAL POLYMERS | LIPA, ABCG2, ABCB11 | CCR1 3350/4885CHRM2 3086/4885CCR5 3538/4885 |
| US-20140210117-A1 | PHARMACEUTICAL COMPOSITIONS OF DISPERSIONS OF DRUG AND NEUTRAL POLYMERS | LIPA, ABCG2, ABCB11 | CCR1 3350/4885CHRM2 3086/4885CCR5 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.